Loading clinical trials...

Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATION

Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

NCT07035067•PeriPharm

View on ClinicalTrials.gov

Summary

Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. ≥18 years old
•2. Patients with PROC who received \>1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin)
•3. Ability to read and understand French or English
•4. Signature of ICF
•1. ≥18 years old
•2. Current caregiver of a patient with PROC (see definition to be used above) who received \>1 prior line of therapy identified through a screening survey.
•3. Ability to read and understand French or English
•4. Signature of ICF.

Exclusion Criteria

•1. Patients with PSOC, defined as those who:
•1. Have not progressed within less than 6 months after completion of platinum-based chemotherapy or;
•2. Are still on platinum chemotherapy or;
•3. Receive maintenance therapy.
•2. Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose
•1. Caregivers of patients with PSOC (see definition above)
•2. Caregivers of PROC patients who have passed away
•3. Caregivers of platinum-refractory patients (see definition above)

Locations (1)

PROxy Network, an initiative of PeriPharm Inc.

Montreal, Quebec, Canada

Key Dates

Start Date

July 15, 2025

Primary Completion Date

May 1, 2026

Completion Date

June 1, 2026

Last Updated

December 23, 2025

Enrollment

150

ESTIMATED participants

Conditions

Ovarian CancerCaregiver BurdenPatient Burden

Interventions

No intervention

OTHER

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 23, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)